DMAC DiaMedica Therapeutics Inc.companySEC Filings & Insider Trading Activity 2026
Latest DiaMedica Therapeutics Inc. (DMAC) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 30, 2026, a 10-Q quarterly report filed on November 12, 2025, an 8-K current report filed on March 31, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for DiaMedica Therapeutics Inc. (DMAC) (SEC CIK 1401040), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
Frequently Asked Questions
What are the latest DMAC SEC filings in 2026?
DiaMedica Therapeutics Inc. (DMAC) has filed a 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 12, 2025, an 8-K current report on March 31, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did DMAC file its most recent 10-K annual report?
DiaMedica Therapeutics Inc. (DMAC) filed its most recent 10-K annual report on March 30, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view DMAC 10-Q quarterly reports?
DiaMedica Therapeutics Inc. (DMAC)'s most recent 10-Q quarterly report was filed on November 12, 2025. SignalX displays every DMAC 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has DMAC filed recently?
DiaMedica Therapeutics Inc. (DMAC)'s most recent 8-K was filed on March 31, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find DMAC insider trading activity (Form 4)?
SignalX aggregates every DMAC Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does DMAC file with the SEC?
DiaMedica Therapeutics Inc. (DMAC) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new DMAC filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for DiaMedica Therapeutics Inc. (DMAC).
What is DMAC's SEC CIK number?
DiaMedica Therapeutics Inc. (DMAC)'s SEC CIK (Central Index Key) number is 1401040. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1401040 to look up all DMAC filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find DMAC return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from DiaMedica Therapeutics Inc. (DMAC) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of DiaMedica Therapeutics Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 32+ filings.